In a pragmatic trial in adults previously given at least 2 mRNA COVID-19 vaccines, 2023-24 XBB.1.5 vaccines had adjusted effectiveness of 43.6% against symptomatic infection versus a non-randomised unvaccinated group; protein-based vs mRNA did not differ significantly.
RCTn = 909
Yoon et al. Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial)